EE03952B1 - Tagasivoolu inhibiitorid - Google Patents
Tagasivoolu inhibiitoridInfo
- Publication number
- EE03952B1 EE03952B1 EEP199900095A EE9900095A EE03952B1 EE 03952 B1 EE03952 B1 EE 03952B1 EE P199900095 A EEP199900095 A EE P199900095A EE 9900095 A EE9900095 A EE 9900095A EE 03952 B1 EE03952 B1 EE 03952B1
- Authority
- EE
- Estonia
- Prior art keywords
- reflux inhibitors
- reflux
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 238000010992 reflux Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9603408A SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Medical use |
PCT/SE1997/001555 WO1998011885A1 (en) | 1996-09-18 | 1997-09-15 | Reflux inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EE9900095A EE9900095A (et) | 1999-10-15 |
EE03952B1 true EE03952B1 (et) | 2003-02-17 |
Family
ID=20403936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP199900095A EE03952B1 (et) | 1996-09-18 | 1997-09-15 | Tagasivoolu inhibiitorid |
Country Status (35)
Country | Link |
---|---|
US (2) | US6117908A (et) |
EP (2) | EP0936906B1 (et) |
JP (1) | JP4098832B2 (et) |
KR (2) | KR100568659B1 (et) |
CN (1) | CN1117560C (et) |
AR (1) | AR007747A1 (et) |
AT (2) | ATE334700T1 (et) |
AU (1) | AU714370B2 (et) |
BR (1) | BR9711400A (et) |
CA (1) | CA2265615C (et) |
CZ (1) | CZ299997B6 (et) |
DE (2) | DE69736445T2 (et) |
DK (2) | DK0936906T3 (et) |
EE (1) | EE03952B1 (et) |
ES (2) | ES2268227T3 (et) |
HK (2) | HK1022100A1 (et) |
HU (1) | HU224968B1 (et) |
ID (1) | ID19621A (et) |
IL (1) | IL128961A (et) |
IS (2) | IS2329B (et) |
MY (1) | MY122020A (et) |
NO (1) | NO326837B1 (et) |
NZ (2) | NZ504244A (et) |
PL (1) | PL190028B1 (et) |
PT (2) | PT1344524E (et) |
RU (1) | RU2199316C2 (et) |
SA (1) | SA97180522B1 (et) |
SE (1) | SE9603408D0 (et) |
SI (2) | SI1344524T1 (et) |
SK (1) | SK285744B6 (et) |
TR (1) | TR199900591T2 (et) |
TW (1) | TW548104B (et) |
UA (1) | UA61081C2 (et) |
WO (1) | WO1998011885A1 (et) |
ZA (1) | ZA977969B (et) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL189872B1 (pl) | 1996-07-24 | 2005-10-31 | Warner Lambert Co | Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu |
WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
US7319095B2 (en) * | 1999-12-09 | 2008-01-15 | Astrazeneca Ab | Use of GABAB receptor agonists |
SE9904507D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Ab | New compounds |
SE9904508D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Ab | New compounds |
TWI256314B (en) * | 2000-02-09 | 2006-06-11 | Mitsubishi Pharma Corp | Preventive-therapeutical medicament for gastroesophageal reflux disease |
EP1401423A4 (en) * | 2001-05-29 | 2006-08-16 | Depomed Dev Ltd | METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN |
AR033779A1 (es) | 2001-06-08 | 2004-01-07 | Astrazeneca Ab | Compuestos utiles en la enfermedad de reflujo |
SE0102055D0 (sv) * | 2001-06-08 | 2001-06-08 | Astrazeneca Ab | New Compounds |
SE0102057D0 (sv) * | 2001-06-08 | 2001-06-08 | Astrazeneca Ab | New Salts I |
SE0102058D0 (sv) * | 2001-06-08 | 2001-06-08 | Astrazeneca Ab | New Salts II |
GB0209481D0 (en) * | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
US7964609B2 (en) * | 2002-06-20 | 2011-06-21 | Astrazeneca Ab | Use of mGluR5 antagonists for the treatment of gerd |
SE0201943D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
SE0201940D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
SE0201939D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination |
GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
PL377520A1 (pl) * | 2002-12-13 | 2006-02-06 | Warner-Lambert Company Llc | Pochodne pregabaliny przeznaczone do leczenia fibromialgii i innych zaburzeń |
PT1660440E (pt) * | 2003-08-20 | 2012-05-15 | Xenoport Inc | Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização |
EP2354120A1 (en) | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
AU2004272302A1 (en) * | 2003-09-12 | 2005-03-24 | Janssen Pharmaceutica N.V. | Chimeric GABAb receptor |
US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
US20050220863A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist |
SE0401653D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
US7566738B2 (en) * | 2004-11-03 | 2009-07-28 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
US7494985B2 (en) * | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
WO2006071186A1 (en) * | 2004-12-27 | 2006-07-06 | Astrazeneca Ab | Use of gabab receptor agonists |
JP2009521428A (ja) * | 2005-12-23 | 2009-06-04 | アストラゼネカ・アクチエボラーグ | 胃腸疾患治療用のイミダゾール誘導体 |
EP1968946A4 (en) * | 2005-12-23 | 2010-05-05 | Astrazeneca Ab | IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR |
EP1966176A4 (en) * | 2005-12-23 | 2011-08-10 | Astrazeneca Ab | HETEROCYCLIC GABA B MODULATORS |
BRPI0620415A2 (pt) * | 2005-12-23 | 2011-11-08 | Astrazeneca Ab | composto e sais farmaceuticamente e farmacologicamente aceitáveis do mesmo, e enantiÈmeros do composto e sais do mesmo, composição farmaceutica, e, uso de um composto opcionalmente em combinação com um agonista do receptor de gabab, e, métodos para o tratamento de doença, de um distúrbio, e de sìndrome |
KR20080087852A (ko) | 2005-12-23 | 2008-10-01 | 아스트라제네카 아베 | Gaba-b 수용체 조절제 |
WO2008033572A1 (en) * | 2006-09-15 | 2008-03-20 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
JP2010514702A (ja) * | 2006-12-22 | 2010-05-06 | アイロンウッド ファーマシューティカルズ,インコーポレーテッド | 食道障害の治療方法および治療用組成物 |
WO2008086492A1 (en) * | 2007-01-11 | 2008-07-17 | Xenoport, Inc. | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
EP2146996A4 (en) * | 2007-04-18 | 2011-08-03 | Astrazeneca Ab | XANTHIN COMPOUNDS WITH A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATORE EFFECT |
WO2008157408A2 (en) * | 2007-06-15 | 2008-12-24 | Xenoport, Inc. | Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
JP2010534239A (ja) * | 2007-07-25 | 2010-11-04 | アストラゼネカ・アクチエボラーグ | Nerdの治療のための(3−アミノ−2−フルオロプロピル)ホスフィン酸の使用 |
WO2009061934A1 (en) * | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
TWI380812B (zh) * | 2008-01-25 | 2013-01-01 | Xenoport Inc | (3s)-胺甲基-5-甲基己酸前藥之晶形及使用方法 |
EP2250148B1 (en) | 2008-01-25 | 2016-08-17 | XenoPort, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
US20100137442A2 (en) * | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
WO2009117160A2 (en) * | 2008-03-20 | 2009-09-24 | General Mills, Inc. | Compound and method for treatment of gastroesophageal reflux |
US8299291B2 (en) * | 2008-08-07 | 2012-10-30 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
WO2010017498A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing n-hydroxysuccinimidyl carbonates |
EP2403486A1 (en) | 2009-03-03 | 2012-01-11 | XenoPort, Inc. | Sustained release oral dosage forms of an r-baclofen prodrug |
EP2419401A2 (en) * | 2009-04-17 | 2012-02-22 | XenoPort, Inc. | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS |
WO2011113904A1 (en) | 2010-03-17 | 2011-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
WO2013023155A1 (en) | 2011-08-11 | 2013-02-14 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
CA2874737A1 (en) | 2012-06-01 | 2013-12-05 | Lynn Health Science Institute, Inc. | Use of baclofen to treat insomnia |
TW202412754A (zh) * | 2022-06-07 | 2024-04-01 | 瑞士商意梭凱普公司 | 應用於食道黏膜的包含逆流抑制劑的藥物傳遞系統 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004077A1 (en) * | 1986-01-03 | 1987-07-16 | The University Of Melbourne | Gastro-oesophageal reflux composition |
NO882881L (no) * | 1988-06-29 | 1990-01-02 | Trond Nilsen | Anordning for lengdekorrugering av metallplater. |
AU5106790A (en) * | 1989-02-03 | 1990-09-05 | Cambridge Neuroscience Research, Inc. | Method of screening and classifying compounds |
GB9117716D0 (en) * | 1991-08-16 | 1991-10-02 | Lynxvale Ltd | Gaba derivatives and their therapeutic application |
EP0556880A3 (en) * | 1992-01-22 | 1993-10-27 | Glaxo Group Limited | Medical use for atypical beta-adrenoceptor agonists |
GB9408064D0 (en) * | 1994-04-22 | 1994-06-15 | Merck Sharp & Dohme | Nucleic acids |
US5491134A (en) * | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
-
1996
- 1996-09-18 SE SE9603408A patent/SE9603408D0/xx unknown
-
1997
- 1997-09-04 AR ARP970104051A patent/AR007747A1/es unknown
- 1997-09-04 ZA ZA9707969A patent/ZA977969B/xx unknown
- 1997-09-12 ID IDP973172A patent/ID19621A/id unknown
- 1997-09-12 TW TW086113275A patent/TW548104B/zh not_active IP Right Cessation
- 1997-09-15 PT PT03013667T patent/PT1344524E/pt unknown
- 1997-09-15 SK SK305-99A patent/SK285744B6/sk not_active IP Right Cessation
- 1997-09-15 EP EP97942346A patent/EP0936906B1/en not_active Expired - Lifetime
- 1997-09-15 US US08/952,400 patent/US6117908A/en not_active Expired - Lifetime
- 1997-09-15 AT AT03013667T patent/ATE334700T1/de active
- 1997-09-15 BR BR9711400A patent/BR9711400A/pt not_active Application Discontinuation
- 1997-09-15 SI SI9730749T patent/SI1344524T1/sl unknown
- 1997-09-15 NZ NZ504244A patent/NZ504244A/xx not_active IP Right Cessation
- 1997-09-15 EP EP03013667A patent/EP1344524B1/en not_active Expired - Lifetime
- 1997-09-15 DK DK97942346T patent/DK0936906T3/da active
- 1997-09-15 CZ CZ0093099A patent/CZ299997B6/cs not_active IP Right Cessation
- 1997-09-15 WO PCT/SE1997/001555 patent/WO1998011885A1/en active Application Filing
- 1997-09-15 KR KR1020057018539A patent/KR100568659B1/ko not_active IP Right Cessation
- 1997-09-15 EE EEP199900095A patent/EE03952B1/et not_active IP Right Cessation
- 1997-09-15 KR KR1019997002239A patent/KR100553294B1/ko not_active IP Right Cessation
- 1997-09-15 SI SI9730594T patent/SI0936906T1/xx unknown
- 1997-09-15 DK DK03013667T patent/DK1344524T3/da active
- 1997-09-15 NZ NZ334495A patent/NZ334495A/xx not_active IP Right Cessation
- 1997-09-15 TR TR1999/00591T patent/TR199900591T2/xx unknown
- 1997-09-15 AT AT97942346T patent/ATE249212T1/de active
- 1997-09-15 HU HU9903825A patent/HU224968B1/hu not_active IP Right Cessation
- 1997-09-15 CA CA002265615A patent/CA2265615C/en not_active Expired - Fee Related
- 1997-09-15 AU AU44064/97A patent/AU714370B2/en not_active Ceased
- 1997-09-15 PT PT97942346T patent/PT936906E/pt unknown
- 1997-09-15 UA UA99031298A patent/UA61081C2/uk unknown
- 1997-09-15 DE DE69736445T patent/DE69736445T2/de not_active Expired - Lifetime
- 1997-09-15 ES ES03013667T patent/ES2268227T3/es not_active Expired - Lifetime
- 1997-09-15 DE DE69724809T patent/DE69724809T2/de not_active Expired - Lifetime
- 1997-09-15 CN CN97199600A patent/CN1117560C/zh not_active Expired - Fee Related
- 1997-09-15 PL PL97332497A patent/PL190028B1/pl not_active IP Right Cessation
- 1997-09-15 RU RU99107969/14A patent/RU2199316C2/ru not_active IP Right Cessation
- 1997-09-15 IL IL12896197A patent/IL128961A/en not_active IP Right Cessation
- 1997-09-15 JP JP51458198A patent/JP4098832B2/ja not_active Expired - Fee Related
- 1997-09-15 ES ES97942346T patent/ES2206749T3/es not_active Expired - Lifetime
- 1997-09-16 MY MYPI97004296A patent/MY122020A/en unknown
- 1997-10-27 SA SA97180522A patent/SA97180522B1/ar unknown
-
1999
- 1999-03-15 IS IS5001A patent/IS2329B/is unknown
- 1999-03-17 NO NO19991287A patent/NO326837B1/no not_active IP Right Cessation
-
2000
- 2000-02-24 HK HK00101114A patent/HK1022100A1/xx not_active IP Right Cessation
- 2000-09-08 US US09/658,242 patent/US6664069B1/en not_active Expired - Fee Related
-
2003
- 2003-12-23 HK HK03109347A patent/HK1057004A1/xx not_active IP Right Cessation
-
2007
- 2007-03-19 IS IS8623A patent/IS2538B/is unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE249212T1 (de) | Refluxinhibitoren | |
FI963597A (fi) | Isoprenyylitransferaasi-inhibiittoreita | |
NO972930D0 (no) | Fibronectin-adhesjonsinhibitorer | |
FI972160A (fi) | Matriisimetalloproteaasi-inhibiittorit | |
ID19198A (id) | Inhibitor metaloprotease heterosiklik | |
DK1004669T3 (da) | Hidtil ukendte differentieringsinhibitor | |
NO20002121D0 (no) | Benzotiazol-protein-tyrosin-kinaseinhibitorer | |
DK1027332T3 (da) | Hidtil ukendte lactametalloproteaseinhibitorer | |
ID18416A (id) | Inhibitor metaloprotease diheterosiklik | |
DK0958287T3 (da) | Sulfamidmetalloprotease-inhibitorer | |
ID18141A (id) | Inhibitor metaloprotease 1,3-diheterosiklik | |
LV12150A (lv) | Farneziltransferazes inhibitori | |
ID18995A (id) | Amida-amida inhibitor apo b-sekresi/mtp | |
ATE268781T1 (de) | Thrombininhibitoren | |
NO20003256L (no) | ACE inhibitor-MMP inhibitor kombinasjoner | |
ID18417A (id) | Inhibitor ditentat metaloprotease | |
FI971156A (fi) | 5alfa-reduktaasi-inhibiittoreita | |
DE69733263D1 (de) | Markierte elastase-inhibitoren | |
ATE252547T1 (de) | Matrixmetalloproteinaseinhibitoren | |
ATE282629T1 (de) | Thrombininhibitoren | |
DE69720957T2 (de) | Ace-hemmer | |
PT948483E (pt) | Inibidores da farnesil-transferase | |
BR9610514A (pt) | Inibidores cicloantihelmínticos | |
CY2007006I2 (el) | Αναστολεις συνθεσεις απολιποπρωτεϊνης-β |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20031231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20041231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20051231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20061231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20071231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20091231 |
|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20120915 |